The European Union would be receiving upto 300 million doses of COVID-19 vaccine by GSK and Sanofi. Sanofi and GSK collaborated with each other to produce the vaccine candidate, which is based on recombinant protein-based technology and adjuvant technology. European countries like France, Belgium, Germany, and Italy would be manufacturing doses of this vaccine. This is a major breakthrough in fighting against COVID-19.
This is the first major vaccine against COVID-19 and it will be benefit one million Europeans, provided it is safe and effective at the clinical trial stage. The vaccine would be beneficial in tackling the global pandemic of coronavirus.
In a press release statement, the President of GSK vaccines thanked Sanofi for collaborating with them, and reiterated that the vaccine would be available soon in Europe. Both companies have worked hard to scale up operations and introduce a vaccine that will be able to tackle the growing pandemic of COVID-19.
The clinical trial would be conducted by Sanofi, and the phase 3 stage of the trial would be completed by 2020. If the vaccine produces positive results, the team of scientists at Sanofi would be filing for a regulatory approval, which is expected to be completed by the first quarter of 2021. Moreover, Sanofi and GSK have collaborated together to produce an antigen and adjuvant that would produce about one billion doses per year.
Globally, the vaccine would be available through a collaborative effort by Sanofi and GSK
In the United States and the UK, Sanofi and GSK have signed cooperation agreement with the Biomedical Advanced Research and Development Authority. The companies have decided to scale up the production of the vaccine at a global level by the end of 2021/22. The collaboration would include governments and global health organizations.